Researchers have developed a new screening method, EV-SELEX, designed to accelerate drug discovery targeting G protein-coupled receptors (GPCRs), the most abundant protein class in the human body. The technique works by capturing DNA aptamers—short, synthetic DNA strands—that bind directly to GPCRs, a process traditionally slow and inefficient.
GPCRs regulate a vast array of physiological functions, including pain perception and hormone signaling. Because of this central role, they are the targets of the majority of new drugs currently under development. However, finding drug candidates that bind with both high affinity and specificity has remained a major hurdle.
The EV-SELEX approach streamlines the identification of these high-affinity binders, which could significantly shorten the early stages of drug development. By directly capturing receptor-bound aptamers, the method reduces the time and cost typically associated with screening compound libraries.
If validated further, this innovation could accelerate the pipeline for new treatments across many therapeutic areas, particularly those involving neurological, metabolic, and inflammatory diseases. The researchers aim to refine the technique for broader application in pharmaceutical research.
Experts caution that while the method shows promise in proof-of-concept studies, its scalability and effectiveness across diverse GPCR subtypes remain to be demonstrated in larger trials.